Funding for this research was provided by:
Research on rare and intractable diseases, Health and Labour Sciences Research Grants
Text and Data Mining valid from 2020-01-10
Received: 12 September 2019
Accepted: 6 January 2020
First Online: 10 January 2020
Ethics approval and consent to participate
: This is a retrospective study, approved by the Ethics Review Board of Osaka Medical College [No.333 (1964)], the main study center, on July 2016, after which approval was obtained from each of the 13 other participating medical centers. Guardians and patients were provided information by means of an opt-out form.
: Not applicable.
: Tokyo Medical and Dental University (TMDU) received unrestricted research grants for Department of Lifetime Clinical Immunology from AbbVie GK, Ayumi Pharmaceutical, Chugai Pharmaceutical, CSL Behring, Japan Blood Products Organization, Mitsubishi Tanabe Pharma, Nippon Kayaku, Ono Pharmaceutical, Towa Pharmaceutical, and UCB Japan. TMDU paid the salary of Masaaki Mori. The authors declare that they have no competing interests.